Mural cell associated VEGF is required for organotypic vessel formation

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Evensen, Lasse ^a   Micklem, David R ^a,c   Blois, Anna ^a   Berge, Sissel Vik ^a   Aarsaether, Niels ^a   Littlewood Evans, Amanda ^b   Wood, Jeanette ^b,d   Lorens, James B ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BerGenBio   (Norway)

^d S Bio Ltd   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

RAC1 PROTEIN; SCLEROPROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; SIGNAL PEPTIDE; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; BASEMENT MEMBRANE; BRANCHING MORPHOGENESIS; CELL CONTACT; CELL CULTURE; CELL FUNCTION; CELL JUNCTION; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MICROTITER PLATE ASSAY; MOLECULAR IMAGING; MURAL CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; BLOOD VESSEL; CAPILLARY; CELL COMMUNICATION; EXTRACELLULAR MATRIX; METABOLISM; PATHOLOGY; RNA INTERFERENCE;

ADHERENS JUNCTIONS; ANGIOGENESIS INHIBITORS; BASEMENT MEMBRANE; BLOOD VESSELS; CAPILLARIES; CELL COMMUNICATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; RNA INTERFERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67249129599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005798     Document Type: Article

References (42)

1. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165.
2. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
3. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9: 685-693.
4. Bergers G, Song S (2005) The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 7: 452-464.
5. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8: 464-478.
6. Holderfield MT, Hughes CC (2008) Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ Res 102: 637-652.
7. Hall AP (2006) Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. Toxicol Pathol 34: 763-775.
8. Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, et al. (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 153: 543-553.
9. Wilkinson-Berka JL, Babic S, De Gooyer T, Stitt AW, Jaworski K, et al. (2004) Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol 164: 1263-1273.
10. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, et al. (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456: 809-813.
11. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15: 102-111.
12. Wakui S, Yokoo K, Muto T, Suzuki Y, Takahashi H, et al. (2006) Localization of Ang-1, -2, Tie-2, and VEGF expression at endothelial-pericyte interdigitation in rat angiogenesis. Lab Invest 86: 1172-1184.
13. Orlidge A, D'Amore PA (1987) Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 105: 1455-1462.
14. Ding R, Darland DC, Parmacek MS, D'Amore PA (2004) Endothelial-mesenchymal interactions in vitro reveal molecular mechanisms of smooth muscle/pericyte differentiation. Stem Cells Dev 13: 509-520.
15. Hanahan D (1997) Signaling vascular morphogenesis and maintenance. Science 277: 48-50.
16. Uemura A, Ogawa M, Hirashima M, Fujiwara T, Koyama S, et al. (2002) Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 110: 1619-1628.
17. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
18. Korff T, Kimmina S, Martiny-Baron G, Augustin HG (2001) Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. Faseb J 15: 447-457.
19. Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19: 7-16.
20. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, et al. (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731-3736.
21. Bryan BA, D'Amore PA (2008) Pericyte isolation and use in endothelial/ pericyte coculture models. Methods Enzymol 443: 315-331.
22. Donovan D, Brown NJ, Bishop ET, Lewis CE (2001) Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 4: 113-121.
23. Davis GE, Senger DR (2005) Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 97: 1093-1107.
24. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA (1989) An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A 86: 4544-4548.
25. Connolly JO, Simpson N, Hewlett L, Hall A (2002) Rac regulates endothelial morphogenesis and capillary assembly. Mol Biol Cell 13: 2474-2485.
26. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, et al. (2003) Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 264: 275-288.
27. Liu H, Kennard S, Lilly B (2009) NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. Circ Res 104: 466-475.
28. Lilly B, Kennard S (2009) Differential gene expression in a coculture model of angiogenesis reveals modulation of select pathways and a role for Notch signaling. Physiol Genomics 36: 69-78.
29. Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, et al. (2005) Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res 65: 9294-9303.
30. Dejana E (2004) Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 5: 261-270.
31. Kurzen H, Manns S, Dandekar G, Schmidt T, Pratzel S, et al. (2002) Tightening of endothelial cell contacts: a physiologic response to cocultures with smooth-muscle-like 10T1/2 cells. J Invest Dermatol 119: 143-153.
32. Goto F, Goto K, Weindel K, Folkman J (1993) Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 69: 508-517.
33. Bryan BA, D'Amore PA (2007) What tangled webs they weave: Rho-GTPase control of angiogenesis. Cell Mol Life Sci 64: 2053-2065.
34. McKee KK, Harrison D, Capizzi S, Yurchenco PD (2007) Role of laminin terminal globular domains in basement membrane assembly. J Biol Chem 282: 21437-21447.
35. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
36. Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, et al. (2004) Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 113: 516-527.
37. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G (2005) PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7: 870-879.
38. Lorens JB, Bennett MK, Pearsall DM, Throndset WR, Rossi AB, et al. (2000) Retroviral delivery of peptide modulators of cellular functions. Mol Ther 1: 438-447.
39. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, et al. (2004) Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 22: 1567-1572.
40. Lorens JB, Pearsall DM, Swift SE, Peelle B, Armstrong R, et al. (2004) Stable, stoichiometric delivery of diverse protein functions. J Biochem Biophys Methods 58: 101-110.
41. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599.
42. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, et al. (2000) PTK787/ ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189.